Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608465 · ClinicalTrials.gov registry record · Phase 4
Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity
A Phase 4 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT00608465 is a Phase 4 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 4 participants.
The verdict
NCT00608465, a Phase 4 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The combination of high blood pressure and having central obesity is an increasing important factor for heart disease in men and women. It can also lead to the early development of hardening of the arteries and increased risk of a stroke. This study will analyze patients' genetic make up to identify who may be at greater risk for heart disease and strokes in relationship to high blood pressure and central obesity.
Interventions
- DRUG Ramipril
- DRUG Eplerenone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00608465
The ClinicalTrials.gov registry entry for NCT00608465 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ramipril is the first listed.
NCT00608465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00608465 about?
NCT00608465 is a clinical study titled "Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity". The combination of high blood pressure and having central obesity is an increasing important factor for heart disease in men and women. It can also lead to the early development of hardening of the arteries and increased risk of a stroke. This study will analyze patients' genetic make up to identify...
What is the current status of trial NCT00608465?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2006-05. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00608465?
The interventions under investigation include: Ramipril (DRUG), Eplerenone (DRUG).
Who is sponsoring clinical trial NCT00608465?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.